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We report the effects of a synthetic peptide designed to act as a nuclear localization signal on the treat-
ment of tuberculosis. The peptide contains 21 amino acid residues with the following speciﬁc domains:
nuclear localization signal from SV 40T, cationic shuttle sequence, and cysteamide group at the C-termi-
nus. The peptide was complexed with the plasmid DNAhsp65 and incorporated into cationic liposomes,
forming a pseudo-ternary complex. The same cationic liposomes, composed of egg chicken L-a-phospha-
tidylcholine, 1,2-dioleoyl-3-trimethylammonium-propane, and 1,2-dioleoyl-3-trimethylammonium-pro-
pane (2:1:1 M), were previously evaluated as a gene carrier for tuberculosis immunization protocols with
DNAhsp65. The pseudo-ternary complex presented a controlled size (250 nm), spherical-like shape, and
various lamellae in liposomes as evaluated by transmission electron microscopy. An assay of ﬂuorescence
probe accessibility conﬁrmed insertion of the peptide/DNA into the liposome structure. Peptide addition
conferred no cytotoxicity in vitro, and similar therapeutic effects against tuberculosis were seen with four
times less DNA compared with naked DNA treatment. Taken together, the results indicate that the
pseudo-ternary complex is a promising gene vaccine for tuberculosis treatment. This work contributes
to the development of multifunctional nanostructures in the search for strategies for in vivo DNA delivery.
 2011 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
DNA vaccines have become a promising alternative for the
treatment and prevention of different infectious diseases [1–3],
such as tuberculosis [4]. Typically, this kind of vaccine consists of
a modiﬁed bacterial plasmid DNA coupled to a gene sequence that
encodes a desired protein. Regarding the several methods of
in vitro or in vivo DNA administration, the DNA will reach the cell
nucleus, be transcribed into mRNA, and translated to the corre-
sponding protein. If this DNA is captured by specialized antigen
presenting cells (APCs), the endogenously produced protein will
be processed to small peptides and presented on the cell surface,PC, L-a-phosphatidylcholine
osphoethanolamine; DOTAP,
MB-Chol, cholesteryl-3
accharide; ERK, extracellular
4,5-diethylthiazoyl-2-yl)-2,5-
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evier OA license. stimulating the T cell adaptive immune response. Also, the entire
protein could be secreted from the cell and recognized by B cells,
stimulating speciﬁc antibody production [5]. This versatile and
broad range of immune response activation makes plasmid DNA
a very useful tool.
However, naked DNA is rapidly degraded in vivo by extracellular
deoxyribonucleases and exhibits poor cellular uptake. An alterna-
tive to overcoming this difﬁculty is the development of safe and
efﬁcient gene carriers [6]. In this context, cationic liposomes can
be used as non-viral carriers, protecting and directing gene mate-
rial to the cells [7,8]. The mechanism of DNA transfection by cat-
ionic liposomes has been studied by many authors, and these
gene carriers are well known to deliver DNA efﬁciently into the
cytosol [9–12]. After DNA release into the cytosol, transfection suc-
cess still depends on DNA trafﬁcking toward the nucleus, and its
transport across the nuclear envelope still remains one of the most
important barriers [13].
During cell division, eukaryotic cells have a disordered nuclear
envelope, facilitating DNA entrance. However, if the cell is not
dividing, the nuclear envelope is an important barrier for macro-
molecules, such as plasmid DNA [13,14]. The nuclear envelope con-
sists of a highly ordered membrane containing pores that allow the
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be transported through the nuclear pore by specialized cargo pro-
teins, and one well-known transport mechanism is through nucle-
ar localization signals (NLS). NLS basically consist of a short
peptide sequence within proteins that allows association of the
molecule with speciﬁc cargo proteins that provide nuclear trans-
port [17]. In this context, NLS represents an additional strategy
and can be incorporated into non-viral gene carriers, such as lipo-
somes, focusing the improvement of plasmid DNA delivery inside
the nucleus to overcome nuclear macromolecule exclusion. Differ-
ent research groups have designed cationic synthetic peptides con-
taining NLS, increasing in vitro and in vivo transfection rates [18].
The overall cationic nature of peptides allows DNA condensation.
Byrnes and colleagues covalently coupled the M9 sequence to the
cationic peptide (scrambled sequence of the cationic SV40 T anti-
gen—KCRGKVPGKYGKG) [19]. The binary DNA/peptide complex
was associated to lipofectamine (cationic lipid carrier) and
in vitro transfection increased 20-fold. Recent studies demon-
strated that lipofectamine (commercial cationic lipid vector) asso-
ciated with DNA/peptide containing the minimal SV40 T-antigen
NLS (EGPKKKRKVG) and a scrambled version of SV40
(EKRGKVKPKG) successfully transfected cells. Relative to lipid
alone, peptide–lipoplexes enhanced in vitro transfection by up to
4.6-fold. The presence of the peptide in the lipoplex increased
the internalization efﬁciency up to 4.5-fold, decreased the percent-
age of lysosomal DNA by 2.1-fold, and increased the efﬁciency of
nuclear accumulation by 3.0-fold [20]. In an in vivo model, Schirm-
beck and colleagues demonstrated that mice immunized with DNA
encoding the hepatitis B surface antigen (HBsAg) coupled to NLS
exhibited a 10–15-fold increase in HBsAg-speciﬁc antibody pro-
duction compared with uncoupled vector [21]. Moreover, in Leish-
mania major challenged mice, immunization with linear DNA
coupled with NLS offered greater protection than a prime-boost
administration protocol [22].
We developed a DNA vaccine encoding the 65-kDa heat shock
protein gene fromMycobacterium leprae (DNAhsp65), which exhib-
its prophylactic and therapeutic effects on mice with tuberculosis
(TB) [23–26]. This vaccine elicits robust CD4 and CD8 memory T
cells, with CD8 being the prominent cell population, resulting in
cytotoxic activity and IFN (interferon)-c cytokine production
[27,28], fundamental elements for killing mycobacteria. Further-
more, DNAhsp65 immunotherapy suppressed TH2 cytokine levels
(which oppose IFN-c effects) and controlled the intensity of local
inﬂammation [29,30]. In this sense, the ﬁne-tuning of the host im-
mune system induced by DNAhsp65 administration is the key for
optimal results in combating the Mycobacterium tuberculosis
pathogen.
Although these results were encouraging, the amount of plasmid
DNA necessary for this goal was high. Thus, our research group
developed a cationic liposome containing DNAhsp65 containing
the lipids 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP),
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and L-a-
phosphatidylcholine (EPC) to sustain protection against TB and de-
crease the administered dose of DNA. The lipid compositionwas the
same as originally developed by Perrie and colleagues [31]; there-
fore, the DNA content was increased in the lipid structures and then
complexed with preformed dehydrated–hydrated vesicles (DRV).
Preclinical results demonstrated the prophylactic potential of lipo-
some genetic vaccine, with low cytotoxicity added to the advantage
of being a single-dose intranasal vaccine with advantageous results
for DNA complexed with DRV liposomes instead of conventional
encapsulation [32,33]. Thus, in the present study, our aim was to
design a non-viral gene carrier with multifunctional domains that
combines a new synthetic peptide containing a NLS with
DNAhsp65/cationic liposome (previously developed [32,33]) useful
for tuberculosis treatment. The pseudo-ternary (NLS/DNA/cationicliposome) complex was characterized according to its physical–
chemical properties, including average diameter, zeta potential,
gel retardation assay, and accessibility to DNA ﬂuorescent probe,
and it was also evaluated for cytotoxicity in vitro and therapeutic ef-
fect in vivo.
2. Materials and methods
2.1. Materials
Plasmid pVAX1 encoding no gene (DNAmock) or pVAX-hsp65
encoding a 65 KDa heat shock protein from M. leprae (DNAhsp65)
was designed for a tuberculosis gene vaccine and supplied by the
Center for Tuberculosis Research, Medical School of São Paulo Uni-
versity at Ribeirão Preto [4]. EPC, DOPE, and DOTAP chloride salt
were purchased from Avanti Lipids and used without further
puriﬁcation.
2.2. Peptide synthesis and puriﬁcation
The KCRGKVPGKYGKGPKKKRKVC-amide, the NLS, was synthe-
sized as described previously [34]. The crude peptide was submit-
ted to O2 oxidation in aqueous solution at neutral pH for 20 h.
Peptide puriﬁcation was carried out on a Waters 510 HPLC instru-
ment using a Vydac C18 preparative column (22-mm internal
diameter, 250-mm length, 70-Å pore size, 10-lm particle size).
The peptide was eluted with a linear gradient using H2O containing
0.1% TFA (solvent A) and 60% acetonitrile in H2O containing 0.1%
TFA (solvent B). A linear gradient (25–55% B) over 90 min with a
ﬂow rate of 10 mL/min and UV detection at 220 nm was used.
The fractions were screened under isocratic conditions in a Chro-
molit C18 analytical column. Pure fractions of the S-S cyclized pep-
tide were pooled, lyophilized, and characterized for homogeneity
by analytical HPLC (Waters Associates, Milford, MA, USA), mass
spectrometry on RP-HPLC/MS (Micromass, Manchester, UK), and
amino acid analysis (Biochrom 20 Plus, Amersham Biosciences,
Uppsala, Sweden).
The 21 amino acid residues of the synthesized peptide had the
following speciﬁc domains and characteristics: (i) NLS from SV 40 T
(simian virus), 7 residues (PKKKRKV) [35], (ii) cationic amino acid
sequence derived from SV 40 T, shuttle sequence with 13 residues
(KCRGKVPGKYGKG) [19,36] with the purpose of improving electro-
static interactions with DNA, (iii) a cysteamide group at the C-ter-
minus [37,38], which was also acetylated at the N-terminus to
increase transfection efﬁciency, and (iv) because this peptide con-
tains two cysteine residues, we promoted cyclization to avoid any
uncontrolled disulﬁde bridge formation during complexation with
DNA.
2.3. Preparation of binary (NLS/DNA) and pseudo-ternary (NLS/DNA/
cationic liposomes) complexes
The binary NLS/DNA complex was formed by adding the appro-
priate amount of peptide to DNA aqueous solution while vortexing
for 40 s. The binary complex was incubated at 4 C for 10 min be-
fore use. The peptide/DNA proportion was established in terms of
molar charge ratio (+/) between the peptide positive charges
(NHþ4 ) and DNA negative molar charges (PO
3
4 groups) (RNLS+/DNA).
This balance was based on the physiological pH. In this special
case, 1 mol of peptide (Mw = 3484.97) corresponds to 10 mols of
positive charge and 1 lg of DNA corresponds to 3 nmols of nega-
tive charge [39].
The pseudo-ternary complex was obtained by adding the binary
complex to the cationic liposomes while vortexing for 40 s. This
complex was kept at room temperature for at least 30 min before
physico-chemical and in vivo characterization. This formulation
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proportion of cationic liposome to DNA was kept the same as in
our previous study (molar charge ratio between cationic lipid
charge and DNA negative molar charge, RLIP+/DNA, of 10) [32].
The cationic liposomes were prepared as described previously
[32,33]. Brieﬂy, the lipid stock solutions in chloroform were added
in a round ﬂask, and the thin ﬁlm was obtained under a vacuum.
After hydration at 16 mM in water, the liposomes were extruded
in two polycarbonate membranes at 12 kgf/cm2 (15 times). The ex-
truded liposomes were freeze-dried for 24 h and rehydrated at
64 mM (NaCl 1.44%) to obtain ‘‘empty’’ dehydrated–hydrated ves-
icles (DRVs). This NaCl concentration was selected for the ﬁnal
pseudo-ternary complex to achieve 0.9% NaCl. Fig. 1 presents a
schematic diagram of pseudo-ternary complex formation.
2.4. Physico-chemical characterization
2.4.1. Average diameter and zeta potential for the binary (NLS/DNA)
and pseudo-ternary (NLS/DNA/cationic liposome) complexes
The average hydrodynamic diameter and size distribution for
the pseudo-ternary complex were determined by dynamic light
scattering (Zetasizer 3000 – Malvern) using a Ne–He laser and
measuring a scattering angle of 173. The average diameter of
the binary DNA/peptide complex was obtained by optical micros-
copy (Leica model DMLM) with image acquisition (Leica Qwin500
software). In this case, the average diameter and standard devia-
tion were estimated after acquiring different images and measur-
ing at least 300 particles. The zeta potential was measured using
Zetasizer 3000—Malvern by diluting the binary or pseudo-ternary
complex in an appropriate volume of saline solution (0.9% NaCl)
at pH 6.4 and 25 C.
2.4.2. Gel retardation assay for determining the molar charge ratio for
complete DNA complexation with NLS (RNLS+/DNA)
Determination of the molar charge ratio for complete DNA com-
plexation with NLS (RNLS+/DNA) was based on Eastman et al.’s
method for DNA/liposome complex [40] adapted for peptide/
DNA. Basically, two micrograms of DNA was complexed with the
NLS at different molar charge ratios (RNLS+/DNA) and incubated at
room temperature for 10 min. Six microliters of bromophenol blue
(15% Ficoll 400, 0.1% cyanol xylene, 0.1% bromophenol blue) was
added to the samples, which were electrophoresed in a 0.75% aga-
rose gel containing 0.25 lg/ml ethidium bromide in 40 mM Tris–
acetate buffer solution, 1 mM EDTA TAE 1 at 70 V for 40 min.
The EtBr-stained DNA bands were visualized and photographed
on an ultraviolet transilluminator.
2.4.3. Plasmid DNA accessibility
DNA accessibility to the ﬂuorescence probe (Pico Green) in the
binary and pseudo-ternary complex was determined at differentFig. 1. Schematic representation omolar NLS/DNA ratios (RNLS+/DNA). A working solution was pre-
pared by diluting the Pico Green stock solution 200 times in TE buf-
fer (10 mM Tris–HCl/1 mM EDTA, pH 7.5). For the NLS/DNA binary
complex, 50 ll of DNAhsp65 solution (1 lg/ml) was complexed
with 50 ll of NLS at different concentrations to form complexes
at different RNLS+/DNA. For the NLS/DNA/cationic liposome pseu-
do-ternary complex, 33 ll of DNAhsp65 solution (1 lg/ml) was
complexed with 33 ll of NLS at different concentrations to form
complexes at different RNLS+/DNA. Binary complex was added to
34 ll of liposome dispersion at the same DNA/cationic liposome
molar charge ratio (RLIP+/DNA of 10, according to [32]). The binary
or pseudo-ternary complex was incubated at room temperature for
10 min. One hundred microliters of the working solution was
added to the complexed mixture and incubated for 2–4 min. The
intensity of the ﬂuorescence was then measured using a plate ﬂuo-
rimeter (Gemini XS, Molecular Device) using excitation and emis-
sion wavelengths of 485 and 525 nm, respectively, according to
the manufacturer’s speciﬁcations. The ﬂuorescence intensity pro-
ﬁles were expressed as ﬂuorescence intensity (absolute units)
and plotted as a function of the NLS/DNA molar charge ratio
(RNLS+/DNA). This methodology was adapted from Ferrari and col-
leagues [41].
2.4.4. Morphology
Transmission electron microscopy (TEM) and the negative
staining method were used to visualize the morphology of the
pseudo-ternary NLS/DNA/cationic liposome complex based on
our previous work [32]. Brieﬂy, carbon-coated 200 mesh copper
grids with collodion ﬁlm were used. The pseudo-ternary complex
was diluted to 1 mM (based on the total lipid content) and then ap-
plied to the carbon grid. After incubation for 5 min at room tem-
perature, the excess was blotted. One drop of uranyl acetate (1%
w/w in saline solution) was added to the carbon grid and incubated
for 1 min at room temperature before the excess was blotted and
air-dried. A Carl Zeiss CEM 902 microscope equipped with a Casta-
ing–Henry–Ottensmeyer energy ﬁlter was used and the images ob-
tained using a CCD camera (Proscan).
2.5. In vitro cytotoxicity assay
Prior to biological evaluation, all formulations were tested for
endotoxin levels with QCL-1000 Limulus amebocyte lysate. The de-
tected levels were under 0.01 EU/ml, suitable for in vitro and in vivo
assays. The standard 3-(4,5-diethylthiazoyl-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) colorimetric cytotoxicity assay was used
for in vitro cell cytotoxicity [42]. The J774-macrophage cell line
wasgrown inRPMImediumat106 cells/mlandadded to96-well cell
culture plates at 105 cells/well. The cells were incubated for 24 h at
37 C with 5% CO2. Serial dilutions of the binary or pseudo-ternary
complexes or naked DNA in RPMI mediumwere added as describedf the pseudo-ternary complex.
Fig. 2. Gel retardation assay for NLA/DNA complexation. Two micrograms of
DNAhsp65 was complexed at different NLS/DNA molar charge ratios (RPEP+/DNA) in
0.9% saline solution for 10 min at room temperature. Lane 1, DNA (pVAX-hsp65);
lanes 2–10, increasing NLS/DNA molar charge ratios (RNLS+/DNA): 0.2, 0.3, 0.4, 0.5,
0.6, 0.7, 0.8, 0.9, 1.0, respectively.
Fig. 3. Fluorescence proﬁle as a function of peptide/DNA molar charge ratio
(RNLS+/DNA) using the PicoGreen probe in ultra pure water. The complexation
reactions were carried out at room temperature in water. Error bars correspond to
SD of three independent experiments (n = 3).
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then, 100 ll MTT reagent (5 mg/ml in RPMI)was added to eachwell.
MTTwas allowed to incubate with the cells for 4 h. The supernatant
was aspirated, and 100 ll of isopropanol and 0.1 mol/l HCl were
added to eachwell. After plate agitation, the solubilized compounds
were read with a spectrophotometer set at 570 nm. Cell survival at
the end of treatment was calculated as a ratio of the percentage of
control cells (macrophages incubated with only media). All assays
were performed in quadruplicate.
2.6. In vivo M. tuberculosis infection
2.6.1. Culturing and infection
The H37Rv strain ofM. tuberculosis (American Type Culture Col-
lection, Rockville, MD) was grown in 7H9Middlebrook broth (Difco
Laboratories, Detroit, MI) for 7 days. The culture was harvested by
centrifugation and the cell pellet re-suspended in sterile phosphate
buffered saline (PBS) and vigorously agitated. The homogeneous
suspension was ﬁltered through a 2-lm ﬁlter (Millipore, Bedford,
MA). Because CFU determination takes 4–6 weeks, we used ﬂuo-
rescein diacetate (Sigma, Saint Louis, MO) and ethidium bromide
staining [43] to rapidly assess the viability of M. tuberculosis cul-
tures upon infection. An anterior midline incision was made to ex-
pose the trachea. A 30-gauge needle attached to a tuberculin
syringe was inserted into the trachea and intratracheal dispersion
used to introduce 105 viable CFU ofM. tuberculosis H37Rv in 100 ll
of PBS into the lungs [44]. Control mice received only intratracheal
PBS.
2.6.2. Gene therapy
DNAtreatmentwas initiated30 days after TB inductionby inject-
ing 50 lg of plasmid DNA in 50 ll of saline into the quadriceps
muscle of each hind leg on four occasions at 10-day intervals. Alter-
natively, separate groups of mice were treated with the binary or
pseudo-ternary complex (RNLS+/DNA and RLIP+/DNA of 10 in the case
of the pseudo-ternary complex) via the intranasal route at the same
time point. Ten days after the last dose, mice were killed and bacte-
rial growth assessed in the lungs after tissue homogenization.
2.6.3. Determination of M. tuberculosis colony forming units (CFU) in
the lungs
Recovery of M. tuberculosis was performed as described previ-
ously [24]. Brieﬂy, the number of live bacteria recovered from
the lungs was determined as CFU by plating 10-fold serial dilutions
of homogenized tissue on Middlebrook 7H11 agar (Difco) incu-
bated at 37 C. Colonies were counted after 28 days. Results are ex-
pressed as log10 of CFU/g lung.3. Results
3.1. Binary NLS/DNA complexation
The DNA complex with the NLS peptide was evaluated by gel
retardation assay. The peptide/DNA molar charge ratio (RNLS+/DNA)
that completely retains the DNA in the binary complex was 0.5
(Fig. 2).
DNA accessibility to the ﬂuorescence probe was determined at
different molar charge ratios (RNLS+/DNA) for the binary NLS/DNA
complexes (Fig. 3).
All complexations were carried out with the same amount of
DNA, only changing the amount of peptide. Increasing the amount
of peptide (NLS) decreased the ﬂuorescence (Fig. 3), even after
complete DNA incorporation into the complex at RNLS+/DNA 0.5
(Fig. 2). However, two main regions, one with small decay
(RNLS+/DNA = 0.1–0.5) and a second with sharp decay (RNLS+/DNA > 0.5)are observed in Fig. 3. Interestingly, 0.5 is the NLS/DNA molar charge
ratio shown to promote complete DNA incorporation into the peptide
complex in the gel retardation assay. The sharp ﬂuorescent decay pro-
ﬁle observed for R
NLS+/DNA higher than 0.5 indicates that the increased
peptide content decreases DNA intercalation by the ﬂuorescent probe,
suggesting increased DNA condensation.
3.2. Pseudo-ternary NLS/DNA/cationic liposome complex
In order to investigate the inﬂuence of liposome addition on the
binary NLS/DNA complex, we performed similar ﬂuorescent exper-
iments as described in Fig. 3. In this case, the pseudo-ternary com-
plexes were obtained at the same molar charge ratio for cationic
lipid/DNA (RLIP+/DNA) of 10 [32,33] but varying the NLS+/DNAmo-
lar charge ratio (RNLS+/DNA). In other words, we ﬁxed the amount of
DNA and cationic liposome and changed the amount of peptide.
Fig. 4 presents the ﬂuorescent proﬁle, indicating the ﬂuorescence
decay with increasing NLS/DNA molar charge ratio. This behavior
indicates a higher RNLS+/DNA (increased peptide) correlates with
decreased ﬂuorescence as a consequence of lower probe accessibil-
ity to the DNA, even in the presence of cationic liposome. This
behavior suggests that both the peptide and cationic liposomes
protect DNA from ﬂuorescent probe intercalation.
Fig. 4. Fluorescence proﬁle as a function of the NLS(+)/DNA() molar charge ratio
(RNLS+/DNA) using a PicoGreen probe for the pseudo-ternary NLS/DNA/cationic
liposome complex. The complex reactions were carried out at the same DNA and
cationic lipid concentration (RLIP+/DNA = 10). Error bars correspond to SD of three
independent experiments (n = 3).
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highest level of ﬂuorescent decay (Figs. 3 and 4) to study the for-
mation of the pseudo-ternary complex (NLS/DNA/cationic lipo-
some). The corresponding average diameters and zeta potentials
are presented in Table 1. We used the binary complex (NLS/DNA)
as a control.
Our protocol to obtain the pseudo-ternary complex was based
on two steps: the ﬁrst was related to the peptide/DNA complexa-
tion and the second involves the complexation reaction between
the binary NLS/DNA complex with cationic liposomes. Interest-
ingly, when we obtained the binary complex, we were able to iden-
tify the presence of large particles (heterogeneous distribution)
that could be observed by optical microscopy. We estimated the
average diameter as 31 lm after acquiring different images and
measurements of various particles (Leica Qwin500 software). The
zeta potential of the binary complex was 1.5 mV (Table 1).
Surprisingly, the larger particles disappeared after the addi-
tion of the binary complex to the cationic liposome. We ob-
served that the pseudo-ternary complex presented as two
populations, the most relevant being approximately 250 nm
(95.23% in terms of the number of particles) with a zeta poten-
tial of 11.3 mV (Table 1).Table 1
Physico-chemical properties of the pseudo-ternary complex containing the peptide
with nuclear localization signal (NLS), DNAhsp65, and cationic liposomes.a
Complex type Mean diameter Zeta potential
nm ± SDb (%)c mV ± SDd
NLS/DNA/cationic liposome 248.9 ± 37.02 (95.23) 11.3 ± 3.4
(Pseudo-ternary) 975.7 ± 195.9 (4.77)
NLS/DNA
(Binary) – control 31,000 ± 17,000 e 1.5 ± 8.25
a Liposome composition—EPC:DOTAP:DOPE 50:25:25 M. Pseudo-ternary com-
plexes—NLS/DNA/cationic liposome were prepared at molar cationic lipid/DNA
charge ratio (RLIP+/DNA) of 10 and peptide/DNA molar charge ratio (RNLS+/DNA) of 1.
b Mean ± standard deviation (SD). Diameter measurements were performed in
three independent samples.
c Percentages refer to distribution of number-weighted particles.
d Mean ± standard deviation (SD). Zeta potential measurements were performed
in three independent samples.
e Average diameter estimated by optical microscopy using Leica Qwin500 soft-
ware after the acquisition of different images and measurement of at least 300
particles.The morphology of the pseudo-ternary complex was evaluated
by transmission electron microscopy as presented in Fig. 5.
The pseudo-ternary complex assumed spherical-like geometry
(Fig. 5A). The results conﬁrmed our previous evaluation of the
mean diameter and size distribution. Multi-lamellarity was also
identiﬁed in Fig. 5B–D. We found no evidence of larger particles
as identiﬁed for the binary DNA/peptide complex, conﬁrming the
light scattering measurements (Table 1).
3.3. In vitro cytotoxicity evaluation
With the characterized formulations, the next step was to eval-
uate the in vitro cytotoxicity on the J774 cell line. Addition of the
NLS to the liposomes did not induce cytotoxicity (Fig. 6). Interest-
ingly, cell proliferation was augmented when the cells were incu-
bated with liposome plus NLS compared with control (Fig. 6),
which could be related to the adjuvant properties of liposomes
[45]. Increasing the formulation concentration led to re-establish-
ment of the cytotoxicity pattern similar to cells treated only with
NLS. This behavior could be associated with an over-stimulation
of cells, suppressing cell proliferation. Similarly, this phenomenon
was observed in the J774 cell line over-stimulated with lipopoly-
saccharide (LPS), leading to extracellular signal-regulated kinase
(ERK) hyperactivation and interleukin (IL)-12 suppression, culmi-
nating with cell proliferation decrease [46]. Because all formula-
tions presented in this work were endotoxin free, the properties
observed were related to NLS per se.
3.4. Therapeutic effect conferred by NLS addition to the DNAhsp65/
cationic liposome vaccine against TB
Considering that the binary DNAhsp65/cationic liposome com-
plex was effective against TB [47], we further evaluated its poten-
tial with NLS addition in a therapeutic protocol. Infected mice
treated with control formulations carrying plasmid backbone with-
out a gene insert (DNAmock) or NLS did not confer signiﬁcant CFU
reduction (Fig. 7, insert). Though the lack of a therapeutic effect
was observed for DNAhsp65/cationic liposome treatment, the
presence of NLS in this formulation circumvents the inefﬁciency gi-
ven the comparable results to the DNAhsp65-treated group (Fig. 7).4. Discussion
In previous studies, we characterized and evaluated the efﬁcacy
of immunization with DNAhsp65 carried by cationic liposomes
(DNAhsp65/cationic liposome) in animals challenged with M.
tuberculosis, reducing the administered dose with maintenance of
protection [48]. In addition to DNAhsp65 delivery in the cell cyto-
sol being optimized by liposomes, we focused on increasing the
transfection ability of internalized DNA, aiming to improve the
overall process. Therefore, we developed and used a small peptide
sequence with properties that drive other molecules in the cytosol
to the nucleus through classical transportation using a and b
importins [49]. The cationic nature of the peptide used in this work
allowed electrostatic complexation with DNA and further incorpo-
ration into cationic liposomes. Because the development of new
approaches to treat TB is mandatory due to the appearance of mul-
tidrug resistant strains of M. tuberculosis and HIV/TB co-infected
individuals [50], we aimed to evaluate the therapeutic efﬁcacy of
this new formulation.
The binary NLS/DNAhsp65 complex was initially analyzed by
gel agarose electrophoresis (gel retardation assay). We observed
that a peptide/DNA molar charge ratio (RNLS+/DNA) equal or higher
than 0.5 promotes complete DNA incorporation into the peptide
structure (Fig. 2). However, the gel retardation assay does not
Fig. 5. Negative-staining electron micrographs of the pseudo-ternary complex (liposome/DNA/peptide). Liposomes are composed of EPC/DOPE/DOTAP (50:25:25% molar),
the cationic lipid/DNA charge ratio (RLIP+/DNA) was 10, and the peptide/DNAmolar charge ratio (RPEP+/DNA) was 1. Scale bars indicate: 100 nm in (A); 40 nm in (B); and 20 nm
in (C and D).
Fig. 6. In vitro evaluation of cationic liposome cytotoxicity on the J774 macrophage cell line. Conﬂuent cell populations were incubated with NLS, NLS/cationic liposome, NLS/
DNAmock/cationic liposome, or NLS/DNAhsp65/cationic liposome. Macrophages were cultured only in RPMI medium as a control. The formulations were added to the culture
in concentrations ranging from 10–200 lg/ml of DNA, equivalent to 20–400 ll/ml of liposome, for 24 h. After treatment, the MTT reagent was added to the culture medium.
After 4 h of incubation, the medium was removed and 100 ll of isopropanol containing 0.1 mol/l HCl was added to the wells to dissolve the formazan crystals. Values are the
mean ± SD percentage of viable cells compared to the control. The data represent three separate experiments performed in quadruplicate.
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say (speciﬁc intercalating dsDNA, Fig. 3) presents a sharp reduction
of the ﬂuorescent proﬁle for RNLS+/DNA higher than 0.5. This behav-
ior suggests that higher RNLS+/DNA correlates with decreased inter-
calation, probably due to better DNA condensation by the peptide.
Considering the decreased ﬂuorescence (Fig. 3) and previous re-
ports in the literature that mention the beneﬁcial use of peptide in
excess [8,17,36], we selected the RNLS+/DNA of 1 to continue the
evaluation of the average diameter and incorporation into cationic
liposomes.
Electrostatic complexation between the peptide and DNA at a
RNLS+/DNA of 1 generated large particles with an average diameterof 31 lm (Table 1). Population heterogeneity was reﬂected by the
large standard deviation (17 lm). Even the temperature control at
approximately 4 C (to decrease the velocity of the electrostatic
complexation) and intense vortex was not enough to control the
formation of large particles. The zeta potential near neutrality (Ta-
ble 1) allowed uncontrolled complexation [51].
Despite the large size and near neutral zeta potential, we con-
tinued the studies to obtain the pseudo-ternary complex. Our
hypothesis was that the differences in zeta potential between the
peptide/DNA complex (1.5 mV) and ‘‘empty’’ cationic liposome
(26.9 mV) [32] could induce anchorage of the binary complex in
the cationic liposome, generating the pseudo-ternary complex.
Fig. 7. Determination ofM. tuberculosis growth in the lungs of infected mice treated
with different formulations. BALB/c mice were intratracheally infected with
105 Mtb bacilli. Thirty days later, treatment was started, using four doses of naked
DNAhsp65 (totaling 400 lg of DNA) or different liposome formulations (totaling
100 lg of DNA carried by 200 ll of liposome) in 10-day intervals. All control groups
are shown in the inset. Ten days after the last dose, mice were euthanized and CFU
analysis performed. Data represent the mean log10 CFU counts ± SD of six mice per
group for one of three independent experiments. P < 0.05 was considered
signiﬁcant when compared with the saline group.
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formation of large particles between plasmid DNA and synthetic
peptides (oligopeptides with nine amino acids) (13 lm) and subse-
quent mixing with cationic liposomes (DMB-Chol and DOPE/
120 nm), generating uniform nanoparticles [52]. Unfortunately,
these authors did not investigate the zeta potential of the pep-
tide/DNA complex. McKenzie and colleagues also complexed pep-
tides (at different molecular weights and containing different
numbers of cysteines) with DNA [37]. In this case, the formation
of sulﬁde bridges can be controlled by adjusting the pH during
DNA complexation. The authors demonstrated that different pep-
tides can generate particles that range from 50 to 1600 nm,
depending on the peptide type. The mixture of our binary complex
(NLS/DNAhsp65) with the cationic liposomes generated nanoparti-
cles of a controlled size and mean diameter of approximately
250 nm (95% of the population in terms of number distribution).
The large particles disappeared, suggesting the dissociation of
these peptide/DNA micro-structures.
In order to verify whether the peptide was incorporated with
the DNA into the liposomes, we evaluated DNA accessibility by a
ﬂuorescent probe (Fig. 4). We obtained different peptide/DNA com-
plexes (increasing the peptide amount, RNLS+/DNA ranging from 0.1
to 1) and mixed them with cationic liposomes. In all cases, we kept
the proportion of cationic lipid to DNA constant. We observed a
smooth decay in the ﬂuorescent proﬁle, conﬁrming the peptide
inﬂuence on DNA condensation. The smooth decay was due to ex-
cess cationic liposome. We used 10 times more cationic molar
charge from the lipids than the cationic molar charge from the pep-
tide (formulation containing Rlipid+/DNA = 10 and RNLS+/DNA = 1).
The pseudo-ternary complex at RNLS+/DNA = 1 presented with
controlled size, spherical-like shape, and the presence of lamellar
liposomes. Indeed, this pseudo-ternary complex presented a zeta
potential of 11.3 mV. This value is lower than that of the corre-
sponding cationic liposomes/DNAhsp65 vaccine (27.3 mV ± 2.3)
[32], conﬁrming the inﬂuence of NLS on the ﬁnal structure. The
pseudo-ternary complex is still cationic, which is fundamental
for DNA transfection. This formulation was stable in terms of mean
diameter for 4 months (sterile and at 8 C; data not shown).
The behavior related to the homogeneous formation of the
pseudo-ternary complex conﬁrms our hypothesis that the differ-
ence in zeta potential between the binary complex and cationic lip-
osomes is the driving force for the formation of the homogeneous
pseudo-ternary complex. The peptide nature can also be an impor-
tant parameter controlling the binary complex (DNA condensa-
tion). In our case, the peptide was cyclized (sulfate bridges),
which probably contributes to the formation of large NLS/DNA par-
ticles. Additional studies will be conducted by our group to inves-
tigate the complexation of binary complexes (NLS/DNA) at a higher
zeta potential with cationic liposomes.
Because many formulations with cationic charges often exhibit
cell toxicity, which is not desirable for in vivo purposes, we evalu-
ated it in vitro on a macrophage-derived cell line. The addition of
NLS to these formulations did not confer cytotoxicity, showing
similar results as previously designed formulations [32]. Some
components of this complex could maintain the low cytotoxicity,
as the addition of EPC was previously shown to contribute to cyto-
toxicity [33].
We moved forward to evaluate the therapeutic efﬁcacy of these
formulations in mice with TB disease. Surprisingly, the DNAhsp65/
cationic liposome treatment was not effective for killing the myco-
bacteria (Fig. 7). On the other hand, the presence of NLS on this for-
mulation completely changes this scenario, reaching comparable
results in mice treated with naked DNA. Gene therapy with naked
DNAhsp65 consumed 400 lg of plasmid (administration of 100 lg
on four occasions), whereas the pseudo-ternary complex con-
sumed 4-fold less DNAhsp65. Considering that several studies haveshown that the expression of some antigens could be augmented
up to 63 times in the presence of NLS [53], one hypothesis ap-
peared feasible to us. Some cell populations (mainly non-dividing
cells) could be refractory to plasmid DNA transfection, which could
be circumvented with NLS addition, leading to the priming of cells
that were not producing or presenting hsp65 to other immune cell
populations. Curiously, NLS coupling to gene vaccine seems to con-
fer a striking improvement, mainly on the treatment of TB, because
very preliminary results indicate that its presence did not boost the
immune response in a prophylactic model (data not shown). Fur-
ther studies will focus on elucidating the mechanism underlying
NLS participation in different immunization schemes.
Taken together, these results suggest the potentiality of the
NLS/DNAhsp65/cationic liposome pseudo-ternary complex on
improvements in gene therapy against a relevant infectious dis-
ease. The optimization of DNA delivery to the cell nucleus through
NLS activity could boost gene transcription, leading to an effective
immune response against a related pathogen.
5. Conclusion
In this work, we demonstrated the use of a new synthetic pep-
tide containing a NLS (based on the classical Simian Virus SV 40T se-
quence) and its incorporation into the cationic liposome/DNAhsp65
gene vaccine. This pseudo-ternary complex presented therapeutic
effects against TB, even greater than the cationic liposome/
DNAhsp65 gene vaccine and similar to naked DNA, effectively
R.S. Rosada et al. / Journal of Colloid and Interface Science 373 (2012) 102–109 109reducing the total amount of DNAhsp65 administered and via a
painless route. The pseudo-ternary NLS/DNAhsp65/cationic lipo-
some is a promising gene vaccine for TB treatment. In addition,
we were able to produce multifunctional nanoparticles with differ-
ent domains (DNA delivery inside cell and nuclear transport), con-
tributing to the development of nanoparticles for in vivo
applications and gene delivery.Acknowledgments
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